Patients’ Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives
Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik
Journal of Clinical Medicine December 25, 2025 DOI: 10.3390/jcm15010150 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Narrative review Qualitative Peer reviewed |
|---|---|
| Population | Adult patients receiving ketamine or esketamine for depression |
| Interventions | ketamine esketamine |
| Topics | Ketamine Depression Esketamine |
| Keywords | Thematic analysis Qualitative research Narrative review Phenomenology philosophy Experiential learning Medline Psychotherapist Value mathematics Systematic review |
| Citations | 1 |
| Key findings | Patients' perspectives on ketamine treatment for depression coalesce around thematic domains including motivations, treatment phenomenology, post-treatment trajectories, side effects, relational factors, and information needs, underscoring the need for patient-centered service design. |
Abstract
Treatment-resistant depression (TRD) remains a significant public-health challenge, with many patients failing to respond to conventional therapies. Ketamine has emerged as a rapid-acting intervention, but quantitative outcomes alone do not capture patients' lived experiences, which shape engagement, acceptability, and adherence. We conducted a narrative review of qualitative and mixed-methods studies to enable conceptual integration and thematic synthesis of patients' experiences with ketamine treatment for depression, guided by established narrative review methodology and the SANRA framework. A targeted search of MEDLINE and Scopus (November 2025) identified studies reporting adult patients' perspectives on therapeutic ketamine or esketamine use, with qualitative data synthesized iteratively in keeping with narrative review principles. Across the literature, patients' perspectives coalesce around key thematic domains, including motivations and expectations for treatment, the phenomenology of the treatment experience, post-treatment trajectories, side effects and reasons for discontinuation, relational and environmental factors, and information and education needs. By focusing on these thematic groups, the review highlights the experiential dimensions that influence the perceived value and acceptability of ketamine, underscoring the need for patient-centered service design. Integrating these insights can guide the development of ketamine programs that are both evidence-based and aligned with patients' priorities and perspectives.